Background: Despite well-described histopathologic criteria, the distinction of spontaneous abortion from hydatidiform mole and complete hydatidiform mole from partial hydatidiform mole remains a problem because of interobserver and intraobserver variability. The aim of this study was to evaluate the value of two immunohistochemical markers in the differential diagnosis of subgroups of lesions of villous trophoblasts and spontaneous abortions.
Methods: Immunohistochemistry with the P63 and Ki-67 antibody was performed in formalin-fixed paraffinembedded samples of non hydropic abortion (n = 14), partial hydatidiform mole (n = 12), complete hydatidiform mole (n = 12) and choriocarcinoma (n = 12). The Ki-67 and P63 labeling index (number of positive nuclei/total number of nuclei) for villous stromal cells, cytotrophoblasts and syncytiotrophoblasts were evaluated separately by counting 100 cells of each population. Statistical analysis was carried out by χ(2) analysis, and the Mann-Whitney U test. Statistical significance was determined at p < 0.05 on the basis of 2-tailed tests.
Results: None of nonhydropic spontaneous abortions analyzed exhibited positive cytotrotrophoblastic and syncytiotrophoblastic cells for P63. The syncytiotrophoblastic cells were negative for p63 in all of choriocarcinomas. All of choriocarcinomas analyzed exhibited severe expression of Ki-67 in cytotrotrophoblastic cells. None of abortions and partial moles was diffusely labeled with Ki-67.
Conclusions: Ki-67 labeling index in cytotrophoblastic cells is the best index to differentiate between abortion and subgroups of lesions of villous trophoblasts as well as between different subgroups of lesions of villous trophoblasts. Ki-67 is a better marker than P63 to attain this goal.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129081 | PMC |
Mol Genet Genomic Med
January 2025
Department of Biology, Università Degli Studi Di Napoli "Federico II", Naples, Italy.
Background: The KHDC3L gene encodes a component of the subcortical maternal complex (SCMC). Biallelic mutations in this gene cause 5%-10% of biparental hydatidiform moles (BiHM), and a few maternal deletions in KHDC3L have been identified in women with recurrent pregnancy loss (RPL).
Method: In this study, we had a patient with a history of 10 pregnancy or neonatal losses, including spontaneous abortions, neonatal deaths, and molar pregnancy.
Rev Assoc Med Bras (1992)
December 2024
Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
Objective: The aim of this study was to evaluate the serum hCG level in the differential diagnosis between non-molar miscarriage and complete hydatidiform mole in<11 weeks gestation.
Methods: This was a retrospective collaborative cohort study. This study included women with gestational age<11 weeks, with ultrasound evidence of failed pregnancy and available serum hCG pre-uterine evacuation, divided into two groups: the non-molar miscarriage group and the complete hydatidiform mole group.
Aust N Z J Obstet Gynaecol
December 2024
Queensland Trophoblast Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Objectives: To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first-line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).
Methods: Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.
Am J Transl Res
November 2024
Department of Obstetrics and Gynecology, Shanxi Children's Hospital Shanxi Maternal and Child Health Hospital Taiyuan 030001, Shanxi, China.
Objective: To evaluate the clinical efficacy of hysteroscopy in the treatment of molar pregnancy and postoperative residual tissue.
Methods: This retrospective study involved 68 patients who underwent treatment for molar pregnancy in Shanxi Children's Hospital Shanxi Maternal and Child Health Hospital from April 2020 to May 2022. Based on intervention methods, patients were divided into a conventional group (n=33) and a hysteroscopy group (n=35).
Gynecol Oncol
December 2024
Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN).
Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical characteristics, World Health Organization risk score (low-risk 0-6, high-risk ≥7), and treatments/outcomes were evaluated using summary statistics, stratified by initial treatment at a referral center versus locally.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!